Peramivir is a cyclopentane anti-influenza virus drug that can bind to the active site of influenza virus neuraminidase and has inhibitory activity against human influenza A and B viruses. Biochemical analysis showed that peramivir could inhibit the neuraminidase activity of several influenza A and B virus strains, with a median ICso value of 0.2nM (0.09~1.4nM, n=15) for influenza A virus strains, a median ICco value of 1.3nM (0.06~11nM, n=8) for influenza B virus strains, and an ICso value range of 0.06~0.26nM for 2009 HINIA influenza virus strains (swine flu).

This product is an H2 receptor inhibitor, which has the effect of inhibiting gastric acid secretion. It is rapidly absorbed through the gastrointestinal tract after oral administration.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a new type of triazole antifungal drug, which can specifically and effectively inhibit the sterol synthesis of fungi. It is effective against various animal fungal infections such as Candida infection, Cryptococcus neoformans infection, Microsporum infection, Trichophyton, Epidermophyton, Pityrosporum and other infections.

Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. It achieves a bactericidal effect by inhibiting the biosynthesis of microbial cell walls. It is stable to β-lactamase and is still sensitive to many β-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins. It is ineffective against some ultra-extended-spectrum β-lactamases.